Yahoo Web Search

Search results

1. • 

     Mabwell Announces 9MW2821 Clinical Data and Latest Progress to be presented at 2024 ASCO Annual...

     FOX 59 Indianapolis· 3 days ago

     Mabwell (688062.SH), an innovation-driven biopharmaceutical company, announced the data and latest...

2. • Precigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent...

     FOX21 Colorado Springs· 4 days ago

     Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the Company ...

3. • Small Business - The Andalusia Star-News | The Andalusia Star-News

     The Andalusia Star-News· 4 days ago

     The study is examining the safety and tolerability of SPN-817 as adjunctive therapy in adult patients with treatment-resistant seizures, as well as finding effective doses in various treatment-resistant ...

4. • Small Business - Cordele Dispatch | Cordele Dispatch

     Cordele Dispatch· 16 hours ago

     Neuren Phase 2 trial shows significant improvements in Pitt Hopkins syndrome PR Newswire MELBOURNE, Australia, May 27, 2024 Highlights: Statistically significant improvement from baseline assessed ...

5. • Medicenna to Present Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming Sachs 10th Annual...

     Digital Journal· 5 days ago

     Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, announced today that it ...

6. • Calliditas Q1 report, January - March 2024

     FOX 5 San Diego· 5 days ago

     Net sales amounted to SEK 295.5 million, of which TARPEYO® net sales amounted to SEK 278.3 million, for the three months ended March 31, 2024. For the three months ended March 31, 2023, net ...

7. • Biogen (BIIB) to Buy HI-Bio to Expand Rare Disease Pipeline

     Zacks· 5 days ago

     Biogen's (BIIB) acquisition of private biotech, HI-Bio, is set to expand its rare disease pipeline by adding the latter's lead asset, felzartamab.

8. • Sobi North America Gets FDA Fast Track Designation for Rheumatic Disease Complication Treatment

     Morningstar· 3 days ago

     By Ben Glickman Sobi North America said it had received fast track designation from U.S. regulators for its potential treatment for Macrophage Activation Syndrome, a complication of rheumatic diseases. The Waltham, Mass.-based affiliate

9. • Kazia Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirement - Kazia...

     Benzinga· 4 days ago

     Kazia Therapeutics Limited KZIA (Kazia or the company) received a letter on May 22, 2024 from Nasdaq notifying the Company that, while the Company has not regained compliance with the Minimum ...

10. • Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human...

      Morningstar· 5 days ago

      Biogen Inc. (Nasdaq: BIIB) and Human Immunology Biosciences (HI-Bio™), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated ...